Dr. Heimbach on the Need for Multidisciplinary Care in HCC

Video

In Partnership With:

Julie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.

Julie K. Heimbach, MD, transplant surgeon, surgical director of Liver Transplantation, Mayo Clinic, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma (HCC).

A unique aspect of HCC is that patients often have underlying liver disease, commonly cirrhotic liver disease, and so a multidisciplinary treatment approach is necessary, according to Heimbach. For example, oncology experts are needed to treat the liver with systemic therapy, and radiologists are needed to administer liver-directed treatment, Heimbach says. Furthermore, surgical teams may be needed for transplant and resection in these patients, Heimbach adds. 

Treatment decisions depend on tumor characteristics, underlying liver disease characteristics, and systemic comorbidities, Heimbach adds. As such, a multidisciplinary team is needed to determine the best approach for each patient, Heimbach concludes.

Related Videos
Video 10 - "Monitoring and AE Management Strategies with Fruquintinib in CRC"
Video 9 - "FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC"
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles